Full-Time
National Key Account Manager
Pharmacy
Clinigen
501-1,000 employees
Global pharmaceutical services and medicine access
No salary listed
Sydney NSW, Australia + 1 more
More locations: Remote in Australia
Remote
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
 Sales & Account Management (1) |
|---|
Get referred to Clinigen
See people who can refer or advise you
- A bachelor's degree in Business, Marketing, or a related field is required.
- At least 5 years of pharmaceutical sales experience is required, with a focus on over-the-counter products, pharmacy banner groups, and major chain accounts.
- A proven track record of exceeding sales targets and driving business growth is required.
- Strong understanding of the pharmaceutical industry and regulatory environment is required.
- Excellent communication, negotiation, and presentation skills are required.
- The ability to work independently and as part of a team is required.
- Strong analytical and problem-solving skills are required.
- Willingness to travel as required is required.
- Develop and maintain strong relationships with key stakeholders within pharmacy banner groups and major chain accounts.
- Create and implement strategic account plans to achieve sales targets and business objectives.
- Collaborate with internal cross-functional teams to ensure alignment and execution of account strategies.
- Monitor market trends and competitor activities to identify growth opportunities.
- Provide regular updates on account performance and market insights to senior management.
- Drive promotional activities and marketing campaigns to increase product awareness and sales.
- Negotiate pricing and contracts to maximize profitability and market share.
- Conduct regular business reviews with key accounts to assess performance and identify areas for improvement.
- Stay abreast of industry trends and developments to inform business strategy and decision-making.
- Develop and implement a strategic territory plan, including key account management planning for designated customers, and review it regularly in the field with the manager.
- Use customer call reach and frequency effectively based on strategic direction and product potential.
- Develop relationships with medical and scientific key opinion leaders, particularly procurement pharmacists and other defined customers, consistent with business-unit and company strategies.
- Represent the company at continuing pharmacy education events, programs, medical meetings, and scientific conventions.
- Achieve key performance indicators outlined in objectives and field reports.
- Adhere to expenses in line with the set divisional budget.
- Maintain current and comprehensive knowledge of company, competitor, and general products.
- Attend relevant industry conferences to expand knowledge of relevant therapeutic areas.
- Understand issues affecting customers who prescribe the products and patients who use them.
- Carry out duties in adherence to good distribution practice regulations.
- Contribute to a quality-focused mindset and support quality as everyone's responsibility.
- Ensure every team member has the opportunity to work in a safe and healthy work environment.
- Maintain up-to-date knowledge of industry trends, current practices and techniques, publications, regulations, and related developments.
- Maintain up-to-date knowledge of the company's Quality Management System and Group Policies and ensure compliance.
- Ensure company-related activities comply with relevant Acts, legal demands, and ethical standards.
Clinigen provides pharmaceutical services and medicines to help patients access treatments. It revitalizes niche, hospital-only medicines and offers end-to-end services across the product lifecycle through three divisions: Clinical Services, Access and Commercialisation, and Lifecycle Services. The company supports pharma partners with clinical trial supply, managed access programs for unlicensed medicines, market access, and regulatory affairs, distributing products in 100+ countries. Its goal is to ensure ethical patient access by combining product revival with comprehensive lifecycle management on a global scale.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Branston, United Kingdom
Founded
2010
Get referred to Clinigen
See people who can refer or advise you
Simplify's Take
What believers are saying
- PreemieFort approval in Japan opens a new regulated market and premium neonatal channel.
- Shionogi's cefiderocol deal in Australia and New Zealand expands access and royalties.
- Clinigen now serves 1,000-plus pharma partners globally, strengthening recurring service demand.
What critics are saying
- Fitch kept Clinigen at B with negative outlook on 5 June 2025, pressuring refinancing.
- Erwinase production ended in 2025; shortages run through February 2026, threatening access revenue.
- The business depends on a few niche medicines; one supply failure can cascade quickly.
What makes Clinigen unique
- Clinigen secured Japan's first prescription-drug approval for human milk fortifier on 12 February 2026.
- SSI Strategy acquisition closed 21 November 2025, adding 200-plus consultants and biotech advisory depth.
- Greg Skalicky's 20 July 2026 appointment brings Eversana commercialisation expertise to Clinigen.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -3%2 year growth
↓ -3%News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. You are here: Home News Access the latest company news and announcements distributed through Medianet. Technology & Innovation 20/07/2026 21:18 Clinigen appoints Greg Skalicky as Chief Executive Officer. LONDON-BUSINESS WIRE- Clinigen, the global pharmaceutical services company dedicated to accelerating access to critical medicines worldwide, today announced the appointment of Greg Skalicky as Group Chief Executive Officer, effective 20 July 2026. Greg succeeds Dr Varun Sethi, who has served as Acting CEO since September 2025. Skalicky brings more than 30 years of leadership experience, with a unique blend of clinical and commercial expertise in the pharmaceutical, biotechnology and healthcare sectors. He joins Clinigen following a distinguished career leading large-scale organisations, with a track record of driving growth, global expansion, and transformative partnership structures. Most recently he served as President of Eversana, where he designed and implemented the industry's first fully integrated commercialisation model. Prior to Eversana, he held senior leadership roles at Syneos Health (formerly inVentiv Health) and PharmaNet, managing major global client relationships with leading pharmaceutical companies. As Group CEO, Skalicky will lead Clinigen through its next phase of growth, building on the company's strong position as a trusted partner to pharmaceutical and biotechnology companies across clinical trial services, strategic staffing and global compassionate use programs. "Greg is an accomplished healthcare executive with deep industry expertise and a proven ability to scale global organisations," said Paul Carter, Chairman of Clinigen. "His extensive experience across commercialisation, patient access, and pharmaceutical services makes him exceptionally well positioned to lead Clinigen into its next chapter. Our ambition is to offer pharma and biotech clients a fully integrated partner to deliver access to critical medicines across the pharmaceutical lifecycle, and Greg's experience positions him perfectly to deliver on that vision. I would like to thank Varun for his outstanding leadership as Acting CEO, during which time he has continued to strengthen the business and advance our strategic priorities." "I am honoured to join Clinigen at such an exciting time in the company's evolution," said Greg Skalicky. "Clinigen has built an outstanding reputation for solving some of the most complex access and supply challenges in healthcare. The company's mission, expertise, and commitment to patients deeply resonate with me. I look forward to working alongside our talented global team to accelerate growth, enhance client value, and expand access to critical medicines for patients around the world." Clinigen serves more than 1,000 pharmaceutical and biotechnology partners globally and operates across five continents. Under Skalicky's leadership, the company will continue to focus on operational excellence, customer partnership, innovation, and strategic expansion. About Clinigen Clinigen is a global pharmaceutical services company trusted by pharmaceutical and biotechnology organisations worldwide. With decades of experience, Clinigen helps accelerate access to critical medicines across the product lifecycle. Headquartered in the UK with operations across Europe, the Americas, and Asia-Pacific, Clinigen's purpose is to be the global pathfinder accelerating patient access to critical medicines. Clinigen was acquired by Triton Partners in April 2022. Contact details: For further information, please contact: Julian Tyndale-Biscoe (UK)- [email protected] Carrie Young (US)- [email protected] Aanchal Agarwal (APAC)- [email protected] * images - clinigenlogo.jpg download. ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.
Clinigen, a global pharmaceutical services company, has appointed Greg Skalicky as group chief executive officer, effective 20 July 2026. He succeeds Dr Varun Sethi, who served as acting CEO since September 2025. Skalicky brings over 30 years of leadership experience in pharmaceutical, biotechnology, and healthcare sectors. Most recently, he served as president of Eversana, where he designed the industry's first fully integrated commercialisation model. Previously, he held senior roles at Syneos Health and PharmaNet. As group CEO, Skalicky will lead Clinigen's growth, building on its position across clinical trial services, strategic staffing, and global compassionate use programmes. Chairman Paul Carter praised Skalicky's expertise in commercialisation, patient access, and pharmaceutical services, noting his ability to scale global organisations.
Clinigen has secured world-first pharmaceutical approval in Japan for Prolacta Bioscience's PreemieFort Enteral Solution, a human milk-based fortifier. The product is indicated for nutritional management of very low birth weight infants and neonates with weight gain failure. Whilst regulated as infant formula in the US and Europe, PreemieFort became the first human milk-derived product approved as a prescription drug in Japan. The approval was supported by data from the JASMINE Phase III clinical trial in very low birth weight infants. Clinigen served as exclusive licensee and marketing authorisation holder, working with regulators to establish a pharmaceutical pathway where none previously existed. The achievement is particularly significant given Japan's rigorous regulatory standards and status as a global leader in neonatal care.
Acquisition of CSM for initial consideration of $150 million
UK: triton-backed Clinigen acquires SSI Strategy from Amulet Capital.